Pfizer-BioNTech and Moderna’s mRNA platforms are amazing—but they could easily have been overtaken by more conventional rivals.
Tips on how to read the full results from BNT-Pfizer and Moderna, from an expert in evaluating medical evidence.
There’s been even more good news this week, this time from the Oxford-AstraZeneca trials. But a closer look reveals some very shaky science.
Reporting on the big announcement from Pfizer and BioNTech has been a little off the mark. Here’s what we really know right now.
Regeneron’s new Covid drug looks good in early trials, and Trump has called it a miracle. That doesn’t mean it’s going to work.
It’s already looking shaky and politicized on the subject of convalescent plasma. What will happen with vaccines?
The risk of nasty side effects in the Moderna and Oxford trials should be made clear now, before it ends up as fodder for the skeptics.
Two new research papers try to shed some light on a popular theory, but the evidence is still very weak—and could point to confirmation bias.
It’s a good time to sort through what’s known, unknown, and only just beginning to be understood about this months-long intervention.
No one complained about the lack of evidence for 20-second hand-washing. So why did we treat face masks differently?